Collaboration with the pharmaceutical and biotech industry is a key accelerator in the development of therapies for rare genetic diseases. By partnering with companies, Fondazione Telethon gains access to additional financial resources, technologies, and expertise that complement the work carried out within our research institutes.
Industrial agreements are guided by a set of principles that safeguard our mission:
- maintaining ownership of intellectual property and know-how (licensed to partners as appropriate)
- ensuring scientific independence for our researchers
- and securing royalties and returns that are reinvested into research.
Partners are also required to commit to developing the therapies covered by the agreement.
In 2024, Telethon managed 32 active industrial agreements (19 at SR-TIGET and 10 at TIGEM), spanning licensing, research collaborations, material transfer, and confidentiality agreements. Current collaborations include:
Through these and other partnerships, Fondazione Telethon ensures that discoveries made in the laboratory can be translated into accessible therapies for patients, while maintaining the integrity of its scientific mission.
